Background

The rapid vaccination campaign against COVID-19 in Israel relied on the BNT162b2 vaccine. We performed a longitudinal analysis of multiple cohorts, using individual data, to evaluate the effectiveness of the vaccine against new and breakthrough cases.

Methods

We estimated vaccine effectiveness (VE) for 27 consecutive cohorts, each comprised of individuals vaccinated on specific days. VE against new COVID-19 cases was evaluated for five SARS-CoV-2-related outcomes: infection, symptomatic disease, hospitalisation, severe/critical disease and death. For breakthrough cases, rate reduction was evaluated for hospitalisation, severe/critical disease and death. Outcomes were evaluated at predetermined time-periods after vaccination, the last one dedicated to individuals who became SARS-CoV-2-positive 22–28 days after the second dose.

Findings

The highest VE estimates against new cases in ≥16 year old individuals, for all outcomes, were reached at the 15–21 day period after the second dose, ranging between 97.7% (95% CI: 95.9–98.7%) for deaths and 98.6% (95% CI: 97.8–99.1%) for severe/critical disease. VE estimates of the 14–20 day period after the first dose ranged between 54.3% (95% CI: 50.6–57.8%) for infection and 77.3% (95% CI: 71.2–82.1%) for severe/critical disease. VE rose more slowly among ≥80 year old individuals. Rate reductions of breakthrough complications were highest at the 22–28 day period after the second dose, ranging between 47.4% (95% CI: 4.3–71.2%) for death and 66.2% (95% CI: 44.2–79.6%) for severe/critical disease.

Interpretation

The BNT162 vaccine is highly effective in preventing new SARS-CoV-2 cases. Among ≥80 year old individuals, high effectiveness develops more slowly. In breakthrough cases, vaccination reduces complications and death.

Funding

None.

中文翻译：

---

BNT162b2 疫苗对新的 COVID-19 病例和突破性病例并发症的有效性：使用个体化数据进行的全国范围回顾性纵向多队列分析

 背景

以色列针对 COVID-19 的快速疫苗接种活动依赖于 BNT162b2 疫苗。我们使用个体数据对多个队列进行了纵向分析，以评估疫苗针对新病例和突破性病例的有效性。

 方法

我们评估了 27 个连续队列的疫苗有效性 (VE)，每个队列均由在特定日期接种疫苗的个体组成。针对新的 COVID-19 病例的 VE 评估了五种 SARS-CoV-2 相关结局：感染、症状性疾病、住院治疗、严重/危重疾病和死亡。对于突破性病例，评估了住院、严重/危重疾病和死亡的降率。在接种疫苗后的预定时间段内对结果进行评估，最后一次评估专门针对在第二剂疫苗后 22-28 天变为 SARS-CoV-2 阳性的个体。

 发现

对于所有结果，≥16 岁个体中新病例的最高 VE 估计值在第二次接种后 15-21 天期间达到，死亡率为 97.7%（95% CI：95.9-98.7%），死亡率为 98.6%。 % (95% CI: 97.8–99.1%) 为严重/危重疾病。首次给药后 14-20 天期间的 VE 估计范围为感染的 54.3%（95% CI：50.6-57.8%）和严重/危重疾病的 77.3%（95% CI：71.2-82.1%）。 ≥80 岁的个体中 VE 上升较慢。突破性并发症发生率的降低在第二次给药后 22-28 天期间最高，死亡率为 47.4%（95% CI：4.3-71.2%），严重并发症为 66.2%（95% CI：44.2-79.6%）。 /危重疾病。

 解释

BNT162 疫苗对于预防新的 SARS-CoV-2 病例非常有效。在≥80岁的个体中，高效能发展得更慢。在突破性病例中，疫苗接种可减少并发症和死亡。

 资金

 没有任何。